Previous 10 |
March 14, 2019 Palm Beach, FL – March 14, 2019 – According to the Leukemia & Lymphoma Society, the world’s largest voluntary health agency dedicated to blood cancer, In 2018, 60,300 people are expected to be diagnosed with leukemia and that there are an estimat...
CORAL GABLES, FL / ACCESSWIRE / March 13, 2019 / The future of the tech stock market directly related to the ability of companies in the tech industry to combat the growing obstacles facing humanity. In the first few months of 2019, we've seen tech companies share their progress on technol...
Gainers: Akari Therapeutics (NASDAQ: AKTX ) +177% . Pareteum Corporation (NASDAQ: TEUM ) +26% . Clean Energy Fuels (NASDAQ: CLNE ) +25% . Guardant Health (NASDAQ: GH ) +24% . Vera Bradley (NASDAQ: VRA ) +21% . Natera (NASDAQ: NTRA ) +20% . Conatus Pharmaceuticals (NASDAQ: CNAT ...
Thinly traded nano cap Akari Therapeutics ( AKTX +15.4% ) is up out of the gate this morning following its announcement that the FDA has signed off on the endpoints for a pivotal study evaluating second-generation complement inhibitor Coversin for the treatment of pediatric hematopoietic...
Akari Therapeutics (NASDAQ: AKTX ) +19% on announcing that it had a successful Type B, pre-IND meeting with the FDA. More news on: Akari Therapeutics, Plc, Pareteum Corporation, PAVmed Inc., Stocks on the move, Read more ...
HSCT-TMA trial in pediatric patients expected to start Q4 2019 following recent FDA feedback NEW YORK and LONDON, March 13, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and i...
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
Akari Therapeutics Plc Website:
Interim CEO employment contract consists solely of equity compensation Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotec...
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, today announced the successful initial closing of a private placement financing round. This transaction is ...
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan fo...